SEC Comment Letter 0000000000-23-006528 to Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc.
Date: June 16, 2023 · CIK: 0001582554 · Accession: 0000000000-23-006528
AI Filing Summary & Sentiment
File numbers found in text: 333-272580
Letter
United States securities and exchange commission logo June 16, 2023 Jerome D. Jabbour Chief Executive Officer Matinas BioPharma Holdings, Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 Re:Matinas BioPharma Holdings, Inc. Registration Statement on Form S-3 Filed June 9, 2023 File No. 333-272580 Dear Jerome D. Jabbour: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven M. Skolnick, Esq.
Show Raw Text
United States securities and exchange commission logo
June 16, 2023
Jerome D. Jabbour
Chief Executive Officer
Matinas BioPharma Holdings, Inc.
1545 Route 206 South, Suite 302
Bedminster, New Jersey 07921
Re:Matinas BioPharma Holdings, Inc.
Registration Statement on Form S-3
Filed June 9, 2023
File No. 333-272580
Dear Jerome D. Jabbour:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steven M. Skolnick, Esq.